Michael Singer

Neutrolis, Inc. is a biotechnology company located in North Cambridge, MA. The company develops first-in-class therapies that target neutrophils and their pathogenic products, including nets. Neutrolis proprietary platform, Chromatinase™, is based on the naturally occurring enzymes that break down the extracellular chromatin that form nets. The company's lead product, NTR-441, is a patented, first-in-class, engineered DNASE1L3 analog with potential application in COVID-19, ARDS, lupus, rheumatoid arthritis, systemic sclerosis, and other net-mediated diseases. Neutrolis has received two competitive LabCentral Golden Ticket awards from Pfizer and Bristol-Myers Squibb. The company was founded by Abdul Hakkim and Toby Fox. Toby Fox has been the CEO since incorporation.

Pykus Therapeutics, Inc. engages in the development of a dissolvable intraocular surgical device. It offers novel polymer that provides retinal tamponade. The company was founded by James Stefater and Tomasz Stryjewski and is headquartered in Boston, MA.

Anodyne Nanotech, Inc. operates as a preclinical-stage biotech company. It develops differentiated and transdermal forms of high-value drugs. The company is headquartered in Boston, MA.

Cartesian Therapeutics, Inc. manufacturers biological products. The company was founded by Murat Kalayoglu and Michael Singer in 2016 and is headquartered in Gaithersburg, MD.

Topokine Therapeutics, Inc. develops therapies for dermatology and medical aesthetics. Its product, the XAF5 Gel, reduces excess subcutaneous fat. The XAF5 is an adipomodulatory compound that inhibits adipocytes by engaging a cell-surface receptor, resulting in down-regulation of key adipocyte transcription factors. The company was founded in 2010 and is headquartered in Madison, NJ.

HealthHonors provides behavioral economics consulting services. The company is based in Braintree, MA. The company was founded by Murat V. Kalayoglu, Michael S. Singer. HealthHonors was acquired by Tivity Health, Inc., part of Stonepoint Capital LLC from June 28, 2022 on October 14, 2009 for $14.70 million.

Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA.